Opinion|Videos|July 3, 2024

Gene Therapy for Treatment of Duchenne Muscular Dystrophy

Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.

Episodes in this series

Video content above is prompted by the following questions:

  • Provide an overview of delandistrogene moxeparvovec, micro-dystrophin gene therapy, that received accelerated approval for Duchenne muscular dystrophy (DMD) in 2023.
  • Discuss ongoing studies for fordadistrogene movaparvovec gene therapy and other exon skipping therapies.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Related Content